Biotech MVPs are challenging to define because commercial revenue typically only comes after product approval, which many biotechs never achieve.

The focus for biotech companies is on de-risking their technology by obtaining experimental data and developing a viable therapeutic intervention, which is crucial before entering clinical trials.

The last few years have been sobering for the biotech industry, highlighting the need to adapt quickly to survive amidst fierce competition for attention from investors, partners, and talent.

The future of biotech will likely involve products that patients are willing to pay for, focusing on conditions that significantly impact their quality of life.

Focusing on biopharma companies as a target market allows for a more tailored data solution that meets their specific needs.

Biotech founders often make the mistake of not conducting the essential experiments needed to validate their ideas, fearing that failure could jeopardize their startups.

Biotech companies often use their time in Y Combinator to conduct critical path experiments and work with external companies for proof of concept studies, which can advance their regulatory filing status.

Biotech fundraising is increasingly resembling traditional paths seen in software, with many funds showing interest in innovative science companies.

In the current environment, the focus should be on developing products that can demonstrate clear impact on patients, whether through safety or efficacy.